Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > 4-1BB > 41B-M5258

Mouse 4-1BB /TNFRSF9 Protein, Fc Tag (MALS verified)

Order Now

  • Synonym
    TNFRSF9,4-1BB,CD137,CDw137,ILA
  • Source
    Mouse 4-1BB, Fc Tag(41B-M5258) is expressed from human 293 cells (HEK293). It contains AA Val 24 - Leu 211 (Accession # Q8R037-1 ).
    Predicted N-terminus: Val 24
  • Molecular Characterization
    4-1BB Structure

    This protein carries a human IgG1 Fc tag at the C-terminus

    The protein has a calculated MW of 46.7 kDa. The protein migrates as 50-66 kDa under reducing (R) condition (SDS-PAGE).

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
4-1BB SDS-PAGE

Mouse 4-1BB, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
4-1BB MALS images

The purity of Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) is more than 90% and the molecular weight of this protein is around 110-130 kDa verified by SEC-MALS.

Bioactivity-ELISA
 4-1BB ELISA

Immobilized Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) at 2 μg/mL (100 μL/well) can bind Human 4-1BB Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. 41L-H5254) with a linear range of 20-312 ng/mL (QC tested).

 4-1BB ELISA

Immobilized Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) at 2 μg/mL (100 μL/well) can bind Biotinylated Human 4‑1BB Ligand, Fc Tag, Avi Tag (Cat. No. 41L-H82F9) with a linear range of 0.01-0.156 μg/mL (Routinely tested).

Bioactivity-BLI
 4-1BB BLI

Loaded Mouse 4-1BB, Fc Tag (Cat. No. 41B-M5258) on Protein A Biosensor, can bind Human 4-1BB Ligand (71-254), His,Flag Tag (active trimer) (MALS verified) (Cat. No. 41L-H52D4) with an affinity constant of 18.6 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $280.00

Price(USD) : $1870.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:65 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message